William Arnold
Cardiovascular Disease · Atlanta, GANPI 1295734820
Payments from drug & device makers
Across 140 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$742
- Johnson & Johnson$278
- Amgen$196
- Boehringer Ingelheim$190
- Esperion Therapeutics, Inc.$188
- Merck$159
- plus $727 from 11 others
What the payments were for
- Food & beverage$2,472100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 56 | $742 |
| Johnson & Johnson | 17 | $278 |
| Amgen | 11 | $196 |
| Boehringer Ingelheim | 9 | $190 |
| Esperion Therapeutics, Inc. | 4 | $188 |
| Merck | 9 | $159 |
| Pfizer | 6 | $143 |
| E.r. Squibb & Sons, L.L.C. | 9 | $142 |
| Boston Scientific | 6 | $133 |
| AstraZeneca | 6 | $126 |
| Regeneron Healthcare Solutions, Inc. | 1 | $91 |
| Abbott | 1 | $23 |
| Bayer | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Edwards Lifesciences | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,480 in reported general payments places this provider in the 45th percentile of 640 cardiovascular disease providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $135,428 |
| XareltoRivaroxaban | 33 | $35,475 |
| Atorvastatin Calcium | 101 | $1,064 |
| Rosuvastatin Calcium | 72 | $871 |
| Potassium Chloride | 32 | $779 |
| Ezetimibe | 37 | $710 |
| Metoprolol Succinate | 47 | $670 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 14 | $652 |
| Metoprolol Tartrate | 78 | $610 |
| ClopidogrelClopidogrel Bisulfate | 38 | $461 |
| Amlodipine Besylate | 103 | $404 |
| Valsartan | 19 | $400 |
| Carvedilol | 43 | $359 |
| Losartan Potassium | 38 | $323 |
| Furosemide | 56 | $273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $143 | $135,428107 claims |
| Johnson & JohnsonXarelto | $278 | $35,47533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Atlanta
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Bobby KhanAtlanta$1.7M
- Michael MorrisAtlanta$1.1M
- Modele OgunniyiAtlanta$1M
- Joseph MillerAtlanta$771K
- Mani VannanAtlanta$716K
- Gautam KumarAtlanta$639K
- Melvin EcholsAtlanta$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.